Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06806163 · ClinicalTrials.gov registry record · NA

Machine-Learning Prediction and Reducing Overdoses With EHR Nudges

A NA study of Opioid Use Disorder and Opioid Use, sponsored by University of Pittsburgh.

Recruiting
Registry status
NA
Development phase
1,350
Enrollment target
1
Study location

NCT06806163: Recruiting NA study of Opioid Use Disorder and Opioid Use, sponsored by University of Pittsburgh.

NCT06806163 is a NA study of Opioid Use Disorder and Opioid Use that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 1,350 participants, below the 4,651-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06806163, a NA study of Opioid Use Disorder and Opioid Use, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
NA
Development phase
1,350 participants
Enrollment target
1
Study location

Study Summary

The goal of this cluster randomized clinical trial is to test a clinician-targeted behavioral nudge intervention in the Electronic Health Record (EHR) for patients who are identified by a machine-learning based risk prediction model as having an elevated risk for an opioid overdose. The clinical trial will evaluate the effectiveness of providing a flag in the EHR to identify individuals at elevated risk with and without behavioral nudges/best practice alerts (BPAs) as compared to usual care by primary care clinicians. The primary goals of the study are to improve opioid prescribing safety and reduce overdose risk.

Primary Outcome

This outcome measures a composite of three prescribing practices associated with a reduced risk of opioid overdose. Each of the three is assigned a value of one point, with the composite score ranging from 0 to 3: 1. Naloxone prescription: Evidence of a prescription for naloxone. 2. Opioid dosage \< 50 morphine milligram equivalents (MME) per day: No prescriptions exceeding 50 MME/day during the measurement period. 3. No opioid and benzodiazepine overlap: No concurrent prescriptions for opioids

Interventions

  • BEHAVIORAL Usual Care
  • BEHAVIORAL EHR-Embedded Elevated-Risk Flag
  • BEHAVIORAL EHR-Embedded Elevated-Risk Flag with Behavioral Nudges

Study Locations (1)

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 1,350 participants
Start Date 2025-03-10
Est. Completion 2026-05-31
Phase NA
University of Pittsburgh

1,238 total trials

What NCT06806163 shows while recruiting

NCT06806163 is an interventional study that assigns participants to a tested intervention. Its 1,350 participants enrollment target places it among the larger protocols in the corpus, below the 4,651-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (71% lower).

The record links to 4 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Usual Care is the first listed.

NCT06806163 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06806163 about?

NCT06806163 is a clinical study titled "Machine-Learning Prediction and Reducing Overdoses With EHR Nudges". The goal of this cluster randomized clinical trial is to test a clinician-targeted behavioral nudge intervention in the Electronic Health Record (EHR) for patients who are identified by a machine-learning based risk prediction model as having an elevated risk for an opioid overdose. The clinical tr...

What is the current status of trial NCT06806163?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,350 participants. The study started on 2025-03-10. Estimated completion is 2026-05-31.

What conditions does trial NCT06806163 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Opioid Use, Opioid Overdose, Opioids.

What interventions are being tested in trial NCT06806163?

The interventions under investigation include: Usual Care (BEHAVIORAL), EHR-Embedded Elevated-Risk Flag (BEHAVIORAL), EHR-Embedded Elevated-Risk Flag with Behavioral Nudges (BEHAVIORAL).

Who is sponsoring clinical trial NCT06806163?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06806163 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06806163's enrollment target sits among peer trials

1,350 15th of 257 higher than 243 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06318169 · 1,350 participants · Phase 3

    A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  • NCT06605404 · 1,350 participants

    Pan-tumor MRD Study

  • NCT06731608 · 1,344 participants · NA

    OsteoPorotic fracTure preventION System (OPTIONS) Research Study

  • NCT05245227 · 1,358 participants · Phase 3

    Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06806163, the US trial registry maintained by the National Library of Medicine. NCT06806163 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.